Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial.
Amodiaquine
/ therapeutic use
Anemia
/ drug therapy
Antimalarials
/ therapeutic use
Artemisinins
/ therapeutic use
Artesunate
/ therapeutic use
Child
Drug Combinations
Drug Therapy, Combination
Female
Hemoglobins
Humans
Malaria
/ drug therapy
Malaria, Falciparum
/ drug therapy
Mali
/ epidemiology
Pyrimethamine
/ therapeutic use
Sulfadoxine
/ therapeutic use
Journal
The American journal of tropical medicine and hygiene
ISSN: 1476-1645
Titre abrégé: Am J Trop Med Hyg
Pays: United States
ID NLM: 0370507
Informations de publication
Date de publication:
12 10 2022
12 10 2022
Historique:
received:
22
11
2021
accepted:
27
03
2022
pubmed:
23
8
2022
medline:
19
10
2022
entrez:
22
8
2022
Statut:
epublish
Résumé
Intermittent preventive treatment of malaria among schoolchildren (IPTsc) reduces clinical malaria, asymptomatic parasitemia, and anemia. The effects of IPTsc by gender have not been studied longitudinally. We investigated overall IPTsc efficacy and conducted a secondary analysis to explore gender-specific differences. We enrolled schoolchildren aged 6-13 years in an open-label, rolling-cohort randomized controlled trial between September 2007 and February 2013 in Kolle, Mali. Annually, schoolchildren received two full-treatment courses of sulfadoxine-pyrimethamine (SP) plus artesunate, or amodiaquine (AQ) plus artesunate, or no malaria treatment as control. We used mixed-effects generalized linear models to estimate differences in treatment outcomes across groups with interaction terms to explore gender-specific differences associated with Plasmodium falciparum infection, hemoglobin, and grade point averages (GPA) based on standardized testing. Overall, 305 students contributed 4,564 observations. Compared with the control, SP plus artesunate and AQ plus artesunate reduced the odds of P. falciparum infection (odds ratio [OR]: 0.33, 95% CI: 0.26-0.43; OR: 0.46, 95% CI: 0.36-0.59). We found strong evidence of increased mean hemoglobin concentrations (g/dL) in the SP plus artesunate group versus control (difference +0.37, 95% CI: 0.13-0.58). Collectively, schoolchildren given AQ plus artesunate had higher mean GPA (difference +0.36, 95% CI: 0.02-0.69) relative to control. Schoolgirls, compared with schoolboys, given SP plus artesunate had greater improvement in GPA (+0.50, 95% CI: -0.02 to 1.02 versus -0.27, 95% CI: -0.71 to 0.16); interaction P = 0.048, respectively. The IPTsc decreases P. falciparum infections in schoolchildren. Treatment regimens that include longer-acting drugs may be more effective at decreasing malaria-related anemia and improving educational outcomes as observed among girls in this setting.
Identifiants
pubmed: 35995135
doi: 10.4269/ajtmh.21-1218
pii: tpmd211218
pmc: PMC9651524
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Drug Combinations
0
Hemoglobins
0
sulfadoxine-pyrimethamine-artesunate
0
Amodiaquine
220236ED28
Artesunate
60W3249T9M
Sulfadoxine
88463U4SM5
artemisinin
9RMU91N5K2
Pyrimethamine
Z3614QOX8W
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
796-803Subventions
Organisme : FIC NIH HHS
ID : R24 TW007988
Pays : United States
Références
Clin Pharmacokinet. 1996 Apr;30(4):263-99
pubmed: 8983859
Am J Trop Med Hyg. 2015 Oct;93(4):779-789
pubmed: 26283750
Malar J. 2016 Mar 11;15:157
pubmed: 26969283
Ann Nutr Metab. 2006;50(2):85-94
pubmed: 16373990
Malar J. 2018 Apr 3;17(1):147
pubmed: 29615044
BMC Health Serv Res. 2008 Jul 31;8:165
pubmed: 18671874
Am J Trop Med Hyg. 2013 Jun;88(6):1102-1108
pubmed: 23589533
Trop Med Int Health. 2009 Jul;14(7):784-91
pubmed: 19497079
Am J Trop Med Hyg. 1996 Nov;55(5):467-71
pubmed: 8940973
Br J Clin Pharmacol. 2002 Nov;54(5):485-92
pubmed: 12445027
Malar J. 2013 Mar 01;12:82
pubmed: 23452561
Nutrients. 2016 Nov 02;8(11):
pubmed: 27827838
Soc Sci Med. 2010 Jul;71(2):324-334
pubmed: 20413198
PLoS One. 2010 Sep 07;5(9):e12589
pubmed: 20830291
Clin Infect Dis. 2014 May;58(10):1404-12
pubmed: 24621953
PLoS One. 2016 Sep 23;11(9):e0162718
pubmed: 27662368
Lancet Glob Health. 2020 Dec;8(12):e1499-e1511
pubmed: 33222799
Am J Trop Med Hyg. 2015 Oct;93(4):790-7
pubmed: 26324728
Malar J. 2015 Jan 05;14:7
pubmed: 25559587
Malar J. 2015 Nov 14;14:450
pubmed: 26574017
PLoS Med. 2014 Jan 28;11(1):e1001594
pubmed: 24492859
Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):25-34
pubmed: 15331816
Malar J. 2018 Apr 16;17(1):166
pubmed: 29661245
Trop Med Infect Dis. 2020 Sep 17;5(3):
pubmed: 32957604
Infect Immun. 2006 Jun;74(6):3190-203
pubmed: 16714546
Am J Trop Med Hyg. 2012 Sep;87(3):450-459
pubmed: 22826493
Lancet. 2008 Jul 12;372(9633):127-138
pubmed: 18620950
Nat Commun. 2017 Oct 26;8(1):1133
pubmed: 29074880
PLoS One. 2015 Jul 24;10(7):e0134061
pubmed: 26207758
Malar J. 2015 Jun 25;14:260
pubmed: 26109461
Trop Med Int Health. 2014 Nov;19(11):1294-309
pubmed: 25145389